ClinConnect ClinConnect Logo
Search / Trial NCT06872021

Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation

Launched by BEIJING ANZHEN HOSPITAL · Mar 6, 2025

Trial Information

Current as of April 30, 2025

Not yet recruiting

Keywords

Ecmo Iabp Lv Unloading

ClinConnect Summary

This clinical trial is looking at how using a device called an Intra-aortic Balloon Pump (IABP) early during treatment can help patients with a serious heart condition known as cardiogenic shock. Specifically, the trial compares this approach to the usual methods used when patients are on a special life-support system called venoarterial extracorporeal membrane oxygenation (VA-ECMO). The main goal is to see if using the IABP can improve health outcomes for these patients.

To participate in this trial, individuals must be at least 18 years old, have cardiogenic shock, and have successfully received VA-ECMO. However, certain conditions, like severe issues with the heart valves or significant bleeding problems, would make someone ineligible. Participants will be randomly assigned to either receive the IABP or follow the standard treatment. This trial is not yet recruiting patients, but it aims to provide valuable information about how to improve care for people with severe heart problems.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age of ≥18
  • 2. Cardiogenic shock
  • 3. Successful implantation of VA-ECMO
  • 4. Informed consent
  • Exclusion Criteria:
  • 1. Presence of moderate to severe aortic insufficiency
  • 2. Severe peripheral vascular disease
  • 3. Post-cardiotomy cardiogenic shock or bridging to cardiac procedure.
  • 4. VA-ECMO for definite non-cardiac causes
  • 5. Extracorporeal cardiopulmonary resuscitation
  • 6. Implantation of IABP or IMPELLA before VA-ECMO
  • 7. Severe bleeding
  • 8. Terminal malignancy
  • 9. Irreversible neurologic injury
  • 10. Pregnancy or lactation

About Beijing Anzhen Hospital

Beijing Anzhen Hospital is a leading medical institution in China, renowned for its expertise in cardiovascular diseases and comprehensive healthcare services. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and innovation, facilitating the development of new therapies and treatment protocols. With a focus on patient safety and ethical standards, Beijing Anzhen Hospital collaborates with various research entities to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing the understanding of cardiovascular health. Its commitment to excellence in clinical research is underscored by a multidisciplinary team of experienced healthcare professionals and a state-of-the-art facility equipped to support a wide range of clinical investigations.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Trial Officials

Xiaotong Hou, MD, PhD

Principal Investigator

Beijing Anzhen Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported